Rasel Al-Amin

Rasel Al-Amin has a diverse and accomplished academic and professional background. Growing up in Bangladesh, he earned a Bachelor's Degree in Pharmacy from the University of Rajshahi. In 2007, he moved to Sweden to pursue a Master’s in Chemistry and Chemical Engineering at the Royal Institute of Technology (KTH) in Stockholm. After a research stint at the Karolinska Institute, he joined Uppsala University’s molecular tools research unit in 2011 for his PhD studies in Molecular Medicine under Professor Ulf Landegren, completing his PhD in March 2019.

Post-PhD, he co-founded PharmaPrecision AB, a biotech start-up focusing on spatial in situ target-engagement technology. His research expertise includes developing molecular assays for drug discovery and precision proteomics, with a strong background in oligonucleotide-based molecular assays, biochemical and cellular drug discovery, oligonucleotide chemistry, and affinity-based proteomics.

His work has been published in prestigious journals like Nature Methods, Nucleic Acids Research, Diabetologia, Analytical Chemistry, and Communication Biology, and he has presented at notable conferences worldwide. He also held a Thunberg Fellowship at the Swedish Collegium for Advanced Study (SCAS).

In February 2023, he joined the Department of Chemistry at the University of Oxford as a Genomics Medicine Scientist, focusing on therapeutic oligonucleotides targeting mRNA in genomics medicine. He leads research projects in drug discovery, proteomics, bio-conjugation, and molecular assays development, and has significant experience in supervising PhD students and technical personnel.

His passion for research, innovation, and entrepreneurship is evident through his collaborations with academic groups, leadership roles at PharmaPrecision AB, and numerous high-impact publications. He has also taken career breaks to support his family and has completed various courses for commercialization of life science and health care research, business startup and development, intellectual property rights, executive leadership, and project management. In his current position with the Oxford University, he is committed to advancing the genomics medicine field.